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Liquid chromatography-mass spectrometry-based (LC-MS) proteomics uses peak intensities of
proteolytic peptides to infer the differential abundance of peptides/proteins. However, substantial run-
to-run variability in intensities and observations (presence/absence) of peptides makes data analysis
quite challenging. The missing observations in LC-MS proteomics data are difﬁcult to address with
traditional imputation-based approaches because the mechanisms by which data are missing are
unknown a priori. Data can be missing due to random mechanisms such as experimental error or
nonrandom mechanisms such as a true biological effect. We present a statistical approach that uses a
test of independence known as a G-test to test the null hypothesis of independence between the number
of missing values across experimental groups. We pair the G-test results, evaluating independence of
missing data (IMD) with an analysis of variance (ANOVA) that uses only means and variances computed
from the observed data. Each peptide is therefore represented by two statistical conﬁdence metrics,
one for qualitative differential observation and one for quantitative differential intensity. We use three
LC-MS data sets to demonstrate the robustness and sensitivity of the IMD-ANOVA approach.
Keywords: Missing data • peak intensity comparison • quantitative statistical analysis • qualitative
statistical analysis • imputation
Introduction
Measuring quantitative and qualitative changes in the global
proﬁle of proteins by high-resolution mass spectrometry
coupled with liquid chromatography (LC-MS) is key to such
ﬁelds as biomarker discovery and systems biology. An LC-MS
global protein proﬁle is based on whole-cell protein extractions
and the identiﬁcation of enzymatically cleaved peptides, for
which peptide abundances are estimated from the extracted
ion-chromatographic intensities,
1-4 allowing a quantitative
measure of each peptide. This ability to make quantitative
measurements means that one can associate changes in the
global proﬁle of proteins with factor-based changes in the
underlying biological system. Here, factors are the categorical
separations, or groups (e.g., time, exposure, treatment, disease),
of individual samples, deﬁned in controlled experiments to
measure a biological effect. Thus, the output from LC-MS
experiments can generally be deﬁned as a set of measurements
over J peptides, across N samples separated into K groups,
where groups may represent a single or combination of factors.
Similar to microarrays, this experimental design allows statisti-
cal analyses to identify peptides and subsequently proteins that
change based on the “treatment” group.
There are obvious analysis parallels between transcriptomics
and proteomics data since the goal of both approaches is to
measure whole cell complements of biomolecules (RNA and
protein, respectively) up to the limitations of the technologies.
Conceptually, after feature extraction and quantiﬁcation from
the raw data, both technologies result in similar data repre-
sentations, i.e., a matrix where the columns represent distinct
samples (microarray hybridizations or MS runs), and the rows
are associated with the entity measured, which is usually probes
or peptides.
5 Downstream statistical analysis methods have
been designed and validated for microarray data, and many of
these methods have been used extensively in the analysis of
LC-MS and LC-MS/MS proteomics data.
1,5,6 However, as
noted by Li and Roxas,
7 fundamental differences between these
two types of data challenge the appropriateness of statistical
methods designed for microarray analysis when applied to
proteomics data.
One of the key differences between transcriptomics and
proteomics data is the fraction and underlying reason for
missing values in the data matrix. The missing values in
microarray data are typically minimal with modern technolo-
gies and are generally due to issues such as printing artifacts,
scratches, and other processing issues; thus, data are missing
at random. Standard imputation approaches such as K-nearest
neighbors (KNN) work relatively well
8 for random missing data,
and advances in imputation methods such as clustering of
microarray data
9,10 continue to improve downstream analyses.
With proteomic technologies the data can be missing for
numerous diverse reasons. For example, a peptide observed
in one sample may not be observed in other samples due to * Corresponding author. E-mail: bj@pnl.gov.
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splicing, or incomplete enzymatic cleavage; all of these biologi-
cal and experimental variables hinder software-based peptide
identiﬁcation.
11-14 Alternatively, the peptide abundance may
simply be near or below the limits of detection of the platform;
low abundance peptides are more difﬁcult to consistently
identify. Moreover, a peptide may not be observed simply
because it is not present; i.e., the parent protein is not
expressed in a deﬁned experimental groupsthese peptides are
of particular importance because their differential expression
is associated with a biological effect. In effect, a priori it is
unknown if a speciﬁc peptide is missing in an individual
analysis at random or due to some systematic, biological effect
(censored). Proteins that are signiﬁcantly different due to the
presence/absence (qualitatively signiﬁcant) between experi-
mental groups are of special interest in many proteomics
analyses because they have the potential to be used as clinical
biomarkers.
In proteomics analyses, the missing data are often imputed
using simple approaches, and then differential peptide or
protein abundances are identiﬁed by univariate statistical tests
such as a t test or analysis of variance (ANOVA).
1,6,15 However,
imputation of the missing values changes both the mean and
variance structures of the data, and therefore imputation may
invalidate the results of these common statistical tests. Ad-
ditionally, proteomics data sets are often ﬁltered prior to
analysis by some minimum level of occurrence, which is
generally based on arbitrary user rules; e.g., the peptide is
observed in at least 50% of the samples within an experimental
group or across all runs.
16,17 These occurrence ﬁlters aid in the
removal of peptides with inadequate data but may inadvert-
ently remove peptides associated with proteins that have
qualitative differences. An alternate to these simple ﬁlters based
on counts in speciﬁc groups is model-based ﬁltering.
15 A pro-
tein-speciﬁc additive model-based ﬁlter selects, for each pro-
tein, the subset of all identiﬁed peptides that maximize the
protein-level group differences, i.e., produces optimal informa-
tion content. Only those in the optimal set are retained for
further analyses. If the protein does not have a collection of
peptides that produce an identiﬁable model, then none of the
peptides from the parent protein are retained for further
analysis. In many cases, this approach produces biases in the
data similar to the ANOVA ﬁlter because if there are not
adequate data to estimate more than one group mean then
the model will not be identiﬁable for the protein.
The present work describes an approach for the analysis of
proteomics data at the peptide level that combines a statistical
test of peptide intensities with a statistical test for the inde-
pendence of missing data (IMD) from an experimental group.
Our focus herein is to develop a statistically robust approach
to identify a data matrix of peptides that contain signiﬁcance
related to experimental conditions. These peptide lists may
then be interpreted at the peptide level or provide robust
peptide data for processing at the protein level. Speciﬁcally,
we employ a standard ANOVA, or nonparametric equivalent,
when adequate data are present to estimate the peptide mean
and variance for the observed intensity values. To assess the
independence of missing data from an experimental group, we
use a modiﬁed 2 test of independence called a G-test, which
is best suited to data sets with a small number of samples or
with many missing values, a common characteristic of pro-
teomics data. The combination of these two methods, called
IMD-ANOVA, therefore quantiﬁes signiﬁcance using both
peptide intensity and peptide occurrence, therefore capturing
both quantitative and qualitative differences, respectively. A
peptide may be signiﬁcant by only one or both tests.
We demonstrate the robustness of the IMD-ANOVA ap-
proach on two experimental LC-MS data sets. Analyses of these
data sets by a traditional ANOVA-after-imputation approach
resulted in large numbers of signiﬁcant peptides due to a bias
introduced by imputation of the missing data, when either limit
of detection (LOD) or K-nearest neighbor (KNN) methods were
used for imputation. IMD-ANOVA did not introduce this bias,
yielding a more statistically robust result for these data sets.
Lastly, we applied the IMD-ANOVA approach to a proteomics
data set from a cell culture/virus infection experiment, where
the presence of viral proteins was known a priori to demon-
strate that the G-test can more accurately identify peptides
associated with proteins with differential occurrence than
model-based approaches that depend on group averages.
Material and Methods
LC-MS Data Sets. Three LC-MS data sets from independent
MS proteomics experiments were used to compare the G-test
statistical procedure to traditional approaches for statistical
analysis of proteomics data sets. The ﬁrst experimental data
set is associated with a study designed to detect microbial
respiratory infections of mice by analyzing bronchial alveolar
lavage ﬂuid (BALF). The second data set is associated with an
experiment designed to detect changes in protein proﬁles
correlated with smoking status, by analyzing human plasma
samples. The third data set is associated with a time-series
experiment of inﬂuenza infection of Calu-3 epithelial cells; this
data set has the lowest level of run-to-run variability, as well
as known qualitative differences (presence/absence of inﬂuenza
proteins).
All BALF and plasma samples were analyzed using an LTQ-
Orbitrap mass spectrometer (Thermo Electron Corp., Waltham,
MA) with nanoelectrospray ionization. All Calu-3 samples were
analyzed using an Exactive mass spectrometer (Thermo Elec-
tron Corp.). Spectra were collected at 400-2000 m/z with a
resolution of 100k and analyzed using the accurate mass and
elution time (AMT) tag approach.
18 Features from the LC-MS
analyses were matched to AMT tags to identify peptides, using
an initial tolerance of (6 ppm for mass and 0.025% for the LC
normalized elution time (NET). The mass deisotoping process
was performed using Decon2LS,
19 and the matching process
was performed using VIPER.
20 BALF and plasma peptide
abundance data were further processed to remove peptides
identiﬁed with low conﬁdence, using a uniqueness ﬁlter of a
SLiC
21 score of 0.5 and a DelSLiC of 0.2.
21 Calu-3 peptide
abundance data were processed using a SLiC score of 0.35.
Mouse BALF Data Set (BALF). Young male mice (C57/BL)
were subjected to aerosol exposure to one of three organisms:
virulent strains of Francisella novicida (FTN) or Pseudomonas
aeruginosa (PA) or an avirulent strain of F. novicida (MGLA)
containing a mutation in the transcriptional regulator gene
mglA. The C57/BL mice were exposed to one of the above
pathogens and sacriﬁced at one of three time points, 0, 4, or
24 h. The BALF of four mice was analyzed for each exposure
and time point with no technical replicates; additional experi-
mental detail is available.
22,23 For the purposes of this study,
the samples from postinfection time points (4 and 24 h) were
combined into single groups of size 8 for each pathogen.
Proteomic analysis as described above returned 3272 peptides
which were identiﬁed at least once with appropriate conﬁdence
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with either a measured abundance or a missing value. Each
sample data set was log 10 transformed and normalized using
median absolute deviation (MAD) scaling. The ﬁnal, combined
data set thus consisted of a matrix representing 3272 peptides,
with values in four total groups (Control, FTN, PA, and MGLA)
with 12, 8, 8, and 8 samples each, respectively.
Human Plasma Data Set (Plasma). Plasma samples of 27
representative individuals from a cohort of 500 tobacco smok-
ers or nonsmokers were selected for proteomics. The con-
founding factors of age, body mass index (obesity), and gender
were also captured but ignored herein to demonstrate the
statistical approach on a data set with large within- and
between-group variability and with larger sample numbers
(g10) than we had with the mouse infection study (BALF). A
total of 6459 peptides were identiﬁed with statistical conﬁdence
in at least one of 71 data sets (27 plasma samples each with 2
or 3 technical replicates each). The data were log 10 trans-
formed and normalized using a MAD scaling factor, and the
peptide intensities from the technical replicates were averaged
to provide peptide intensities representative of each plasma
sample. The ﬁnal data set thus consisted of a matrix of 6459
peptides, with values for 27 samples separated into two groups
(smokers and nonsmokers), with 13 and 14 samples each,
respectively.
Calu-3 Cell Line/Viral Data Set (VN1203). Calu-3 cells, a
human lung adenocarcinoma cell line, were exposed to avian
inﬂuenza virus A/Vietnam/1203/2004 (H5N1) (VN1203). Cell
monolayers were inoculated with VN1203 for 50 min at 37 °C,
and sham-infected controls were inoculated with medium only.
Following inoculation, monolayers were rinsed and incubated
for times 0, 3, 7, 12, 18, and 24 h. Samples were run with
triplicate technical replicates and returned 25 747 and 288 total
peptides identiﬁed at least once with appropriate conﬁdence
thresholds against either the Calu-3 cell or viral proteins,
respectively. For the purpose of this study, we focus on the
viral peptides because they have known differential occurrence
between the sham and infected groups. To ensure we have a
data set of differential occurrence, we used the 7 h and later
time points for comparative purposes as the 0 and 3 h infected
cells generally have expression of the viral proteins below limit-
of-detection. Peptides with one occurrence were ﬁltered out;
the data were log 10 transformed and normalized using a MAD
scaling factor; and the peptide intensities from technical
replicates were averaged to provide peptide intensities repre-
sentative of each sample. The ﬁnal data set thus consisted of
a matrix representing 255 peptides, with values for 23 samples
separated into two groups (no exposure and inﬂuenza exposed)
of 11 and 12 samples each, respectively. This data set was used
as a benchmark with known qualitative differences since
inﬂuenza proteins should not be identiﬁed in the sham-infected
samples.
G-Test Statistical Procedure. A 2 test of independence is a
statistical test to compare the relationship between two factors
associated with the data.
24 For the missing data problem in
proteomics, these two factors are: (1) the K experimental groups
and (2) the two missing data states (observed or absent). The
null hypothesis is that the number of missing observations is
independent of the groups (e.g., smokers vs nonsmokers). The
number of times each peptide is observed and absent across
the samples associated with group k can be deﬁned as counts
COk and CAk, respectively. On the basis of the total number of
peptides observed (O) and absent (A) from a sample, the
expected number in each group by random chance can be
computed as EOk ) (mOnk)/N and EAk ) (mAnk)/N, where N is
the total number of samples from which mO and mA are the
number observed and absent, respectively (mO + mA ) N); nk
is the number of samples associated with group k; and K is
the total number of groups. Given the counts of observed and
absent peptides and the expected values, the 2 test statistic
can be computed as
The statistical signiﬁcance is then derived from a 2 distribution
with (K - 1) degrees of freedom. If the measured counts and
expected values are similar, then the 2 test statistic will be
small and result in a large p-value; if they are not similar, then
the p-value will be small, indicating that the missing data are
not dispersed as would be expected by random chance.
The 2 test of independence assumes that there are an
adequate number of observations for a normal approximation
of the underlying multinomial distribution. A general rule of
thumb for this assumption is that most expected values used
in the test (EOk and EAk) should be greater than ﬁve.
24 With
proteomics data, expected values of less than 5 are highly likely,
especially for studies with small sample numbers, either
globally or within an experimental group. In addition, for truly
censored peptides, the observed values will be near zero and
consequently result in small expected values. A modiﬁed
version of the 2 test of independence, called a G-test, can be
used where these conditions for the 2 test of independence
are not met. The G-test statistic is computed as
The sum is taken over all nonzero counts, and the statistical
signiﬁcance is still derived from a 2 distribution with (K - 1)
degrees of freedom. Since the censored peptides of interest will
have a large amount of missing data, the G-test is generally
the most appropriate and for simplicity is used exclusively in
this study.
A comparison of the G-test to ANOVA under simulated
scenarios of missing data is given in the Supporting Informa-
tion. The approach for simulating the data and the results of
the simulation are presented in the Supporting Information
methods and associated Figures S1-S3. The results demon-
strate that ANOVA-based analyses in the presence of missing
data do not identify censored peptides as signiﬁcant beyond
what is expected by chance, a key motivating factor of the
G-test approach. The G-test was implemented and evaluated
in MatLab (version 7.10.0.499, R2010a, The Mathworks Inc.,
Natwick, MA). The basic MatLab implementation code for
computing the G-value and associated signiﬁcance value is
given in Figure S4 (Supporting Information).
Statistical Occurrence Filtering. An occurrence ﬁlter is
typically applied to proteomics data to remove peptide obser-
vations for which the data are inadequate for statistical analysis.
For example, if a peptide is observed only one time across a
series of samples, it is evident that there is not enough data to
infer a differential abundance via statistics, regardless of
whether the observation is accurate. Common occurrence
2 ) ∑
k [
(COk - EOk)
2
EOk
+
(CAk - EAk)
2
EAk ] (1)
G ) 2∑
k [COk ln(
COk
EOk) + CAk ln(
CAk
EAk)] (2)
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values for a peptide within a treatment group.
6,16 Since two
observed intensity values are the minimum needed to compute
a SD, this is the minimum occurrence ﬁlter that can theoreti-
cally be applied. However, in practice, ANOVA must have two
groups to compare, so at least two observed intensity values
in each of the two distinct groups is the minimum number
necessary if one is to use ANOVA.
16 This “ANOVA-ﬁlter” can,
however, eliminate peptides with a large number of observa-
tions in a single group, i.e., peptides with a qualitative differ-
ence. Thus, we describe a “G-test ﬁlter” that is based on the
theoretical number of observations of a peptide that any single
group must have to be signiﬁcant in the absence of observa-
tions in any of the remaining groups. The minimum number
of peptides that must be present within a single group can be
solved by a simple integer programming problem for each
group k
This equation can be solved very quickly by setting tk ) 1 and
incrementally increasing by 1 until the G-value results in a
p-value of less than 0.05 based on the 2 distribution. Under
speciﬁc scenarios of large numbers of very small groups, tk may
be undeﬁned, meaning that at tk ) nk the signiﬁcant value is
still not less than 0.05. In this case, tk is set to be equal to nk.
A standard 0.05 threshold is used in this study, but a user can
set any threshold desired to eliminate peptides based on the
needs of the study; for example, a corrected p-value threshold
for multiple comparisons would be called for in some studies.
We combine an ANOVA-ﬁlter (at least two observations in two
distinct groups) and this G-ﬁlter to analyze our real proteomics
data sets (described above). The identiﬁcation of the G-test
ﬁltering values was implemented and evaluated (Version
7.10.0.499, R2010a, The Mathworks Inc., Natwick, MA). Basic
MatLab implementation code for identiﬁcation of the number
of peptides required for G-ﬁltering is given in Figure S5
(Supporting Information).
Results and Discussion
ANOVA is based on a comparison of variance between
treatment groups to variance within treatment groups. In
particular, the ratio of the between to within group variance is
used to compute the test statistic, which is estimated by an
F-distribution.
24 This ratio becomes larger as the quantitative
differences become more extreme, and the p-value computed
from the F-distribution becomes small. However, if adequate
data are not available to compute these estimates of variance,
as is the case with peptides exhibiting a qualitative (occurrence)
difference between groups, the test statistic (F) is undeter-
mined, and no statistical assessment of the data is possible.
Thus, ANOVA-based analyses in the presence of missing data
cannot identify these censored peptides simply due to a lack
of adequate data to estimate a group mean (see Figures S1 and
S2, Supporting Information). We ﬁrst demonstrate how the
G-test ﬁlter can be combined with the ANOVA-ﬁlter (GA-ﬁlter)
to retain the most complete peptide data. Since the peptide
data are the ﬁrst step to protein-level inferences, the identiﬁca-
tion of the appropriate set of peptides for analysis is essential.
Subsequently, we demonstrate how the GA-ﬁlter affects protein
identiﬁcation in comparison to model-based ﬁltering. Lastly,
we compare the G-test directly to ANOVA on imputed data.
Statistical Occurrence Filtering on Peptide Data Sets. Real
proteomics data are generated by a mass spectrometer on a
run-by-run basis, which yields a set of observed and missing
values for a given peptide across runs (which may be samples
or technical replicates of samples), as discussed above. It is
not uncommon in an experiment for a peptide to be observed
in so few runs that the data are inadequate for statistical
analysis, and keeping those peptide observations in the data
set provides no beneﬁt. Not ﬁltering these rarely observed
peptides affects downstream analyses, such as false discovery
rate corrections that rely on the number of comparisons
made.
25 The GA-ﬁltered peptide list is the result of using a
combination of a standard threshold-ﬁlter, i.e., our “ANOVA-
ﬁlter”, as well as our proposed G-ﬁlter (see Methods, eq 3).
Basic MatLab code to implement the GA-ﬁlter is given in Figure
S6 (Supporting Information). The ANOVA-ﬁlter used here is a
threshold of two (at least two values in each of two distinct
groups), although any level can be speciﬁed (three is a common
threshold).
By applying both an ANOVA- and G-ﬁlter to the experimental
BALF and Plasma data sets, no peptides with only one or two
observations passed either ﬁlter, and peptides with three (total)
measured intensities did not pass the ANOVA-ﬁlter, although
these may have passed the G-ﬁlter (if all three observations
were within the same group). This combined ﬁlter reduced the
experimental BALF and Plasma data sets to ∼53.5% and ∼79.2%
of their original data size, respectively. We also examined the
model-based ﬁlter presented by Karpievitch et al.,
15 to deter-
mine if censored peptides would be retained in the context of
the global protein model. Figure 1 gives the exact numbers of
peptides retained by each ﬁlter and their overlap.
For the BALF data set, there were 1347 peptides retained in
the data set when using the ANOVA-ﬁlter. An additional 386
peptides were retained by the G-ﬁlter, of which 345 (∼85.4%)
are signiﬁcant by a G-test at a p-value of less than 0.05 and
minimize: tk
subject to:
COk ) tk
CAk ) nk - tk
∀
j*k
COj ) 0
∀
j*k
CAj ) nk
G ) 2∑
k [COk ln(
COk
EOk) + CAk ln(
CAk
EAk)]

2(G,K - 1) < 0.05
0 < tk e nk
tk integer
(3)
Figure 1. Number of peptides retained by peptide occurrence
ﬁltering and the overlap and uniqueness of the ANOVA, G-test,
and model-based occurrence ﬁlters. Only the G-test ﬁlter retains
peptides that occur predominantly in a single treatment group.
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using a standard Benjamini-Hochberg correction.
25 An ex-
ample of one of these peptides is one for which 11 measured
intensity values were observed: one measurement in each of
the ﬁrst three groups and eight in the last group (FTN). Since
there were not at least two groups with two measured intensity
values, this peptide was deemed as having inadequate data by
the ANOVA-ﬁlter. However, given its observation pattern, one
might infer that this peptide is censored, present in the FTN
group, and missing from the otherssan inference that was
strongly supported by a p-value of less than 1 × 10-5 by the
G-test. The model-based ﬁltering retained fewer peptides (929
total) than either the ANOVA- or G-ﬁlter, and these largely
overlap with the peptides retained by one of the other ﬁlters.
The 29 peptides uniquely retained by the model-based ﬁltering
were all peptides with intensity values present in all four
groups, but with too few values in each group to be retained
by a standard peptide-level ANOVA-ﬁlter or a G-test ﬁlter. The
Plasma data set returned similar results (Figure 1B); a large
number of peptides (512 total) were retained by only the
G-ﬁlter, and the 103 peptides uniquely retained by the model-
based ﬁlter were those with low numbers of observations
(exactly three observations dispersed between the two groups).
Our combination of the G-test ﬁlter and ANOVA-ﬁlter (GA-
Filter) provides a methodology to ﬁlter peptides that have too
little data for downstream statistical analyses, while retaining
peptides with the potential to be either quantitatively or
qualitatively different across groups. Although these occurrence
ﬁlters could potentially be combined with any other ﬁlters of
interest (including a model-based ﬁlter), our results suggest that
the GA-ﬁlter retains the most complete data set to move
forward into the protein inference and quantitation steps.
Inﬂuence of Statistical Occurrence Filtering on Protein-
Level Analysis. The primary goal of this study is the identiﬁca-
tion of an appropriate set of peptides from proteomics data to
carry forward to downstream analyses, most notably the
identiﬁcation of signiﬁcant protein-level differences between
experimental groups. Although we do not address the chal-
lenging problem of inference of signiﬁcant proteins in this
study, it is instructive to examine at the protein level the effect
of the ﬁlters described above.
To evaluate the protein-level information retained by the GA-
ﬁlter versus the model-based ﬁlter, we generated nonredundant
protein lists for each data set using Protein prophet
26 to group
redundant proteins into protein families. Overall, for the BALF
data set many more proteins remain after the ANOVA/G-test
ﬁlter (GA-ﬁlter) than the model-based ﬁlter, 563 versus 347
(Figure 2A). The 12 proteins unique to the model-based ﬁltering
results were each evaluated. These proteins were each repre-
sented in the peptide-level data by a single peptide, for which
there are too few observations to infer quantitative difference
between treatment groups because group variances cannot be
computed. These proteins therefore would presumably be
ﬁltered out by any downstream statistical analyses. For the
Plasma data set, there was a large discrepancy in the number
of peptides retained by the GA- and model-based ﬁlters (Figure
1); however, at the protein level, the proteins that remain after
ﬁltering largely overlap (Figure 2B). The selective pressure of
the model-based ﬁltering approaches to have adequate data
in all groups to compute and maximize a group average result
in fewer proteins retained when more experimental groups are
analyzed (four groups in the BALF data set vs two groups in
the Plasma data set).
For the BALF data set, there were 228 proteins that were
unique to the GA-ﬁlter, and these proteins had peptides that
were only retained by the GA-ﬁlter. About one-half of these
228 proteins are based on a single peptide identiﬁcation (148);
however, approximately 23% (66) are based on evidence from
more than one peptide identiﬁcation. Table 1 gives an example
of a speciﬁc protein (IPI00113057.1) for which seven peptides
are identiﬁed in total. Of these seven peptides, ﬁve are retained
by the G-test ﬁlter, and none are retained by the model-based
ﬁlter. All seven peptides are represented in Table 1 because
even though the other two peptides have inadequate data they
show the same trend where there are zero identiﬁcations in
the Control, MGLA, and FTN groups and one to ﬁve identiﬁca-
tions in the PA group. This qualitative marker is not identiﬁed
by other methods. Approximately 98% of the 66 proteins with
multiple peptide evidence are signiﬁcant for one of the three
exposure groups (protein presence unique to exposure). Only
∼2% are present in control and not expressed in the exposure
groups, qualitatively lost after exposure.
We used the VN1203 data set to further illustrate the ability
of the GA-ﬁlter to correctly retain proteins with qualitative
differences. This data set is an excellent test case because we
know a priori that inﬂuenza proteins should not be detected
in the “sham” infection samples which were not exposed to
the virus, whereas we expect to observe viral proteins in the
virus infected samples. Of the peptides identiﬁed from this
experiment, 255 were identiﬁed against the inﬂuenza genome
and associated with 20 unique inﬂuenza proteins. The GA-ﬁlter
retained all 255 peptides, whereas the model-based ﬁlter
retained only 20 peptides. Figure 3 shows the abundance proﬁle
of the 255 peptides and the number of peptides retained by
each method. These inﬂuenza proteins are known to be
censored by design, and therefore the GA-ﬁlter retains the most
appropriate subset of peptides for downstream protein-level
analyses.
Comparison of the IMD-ANOVA Approach with Tradi-
tional ANOVA Analyses. A common strategy in proteomics
research is to impute the missing values prior to statistical
Figure 2. Number of proteins retained by the GA-ﬁlter versus
model-based ﬁlters for the (A) BALF and (B) plasma data sets.
The GA-ﬁlter is especially important for the BALF data set and
retains many proteins with qualitative differences.
Table 1. Counts of Peptide Observations in Each of the
Groups for the Seven Peptides Associated with IPI00113057.1
peptide
retained
by ﬁlter control MGLA FTN PA
IYGGILSLSEITK yes 0 0 0 5
VSEGNYDIALIK yes 0 0 0 5
VSEYMDWILEK yes 0 0 0 4
SADNLVSGFSLK yes 0 0 0 3
LSTDGSPTR yes 0 0 0 3
TGAISGHSLK no 0 0 0 1
HSASGTPTSIK no 0 0 0 1
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values is to insert, for each given peptide with missing values,
a simple constant deﬁned as 1/2 of the minimum observed
abundance of that peptide.
6 This quasi-LOD imputation as-
sumes that the missing values are due to analytical sensitivity.
More advanced approaches, such as K-nearest neighbors (KNN)
or singular value decomposition (SVD), assume a correlative
structure in the data, so that peptides with similar intensity
patterns can be used to infer the intensities of the missing
peptide values. More recent model-based methods perform
more advanced imputation
15 based on the distribution of the
observed data, but at the caveat of requiring preimputation
ﬁltering that removes many peptides that are signiﬁcant to the
G-test as shown in Figure 1. Therefore, the model-based
imputation approach is not compared.
IMD-ANOVA combines ANOVA to identify quantitative
differences in the presence of missing data with the G-test to
examine the missing data structure for qualitative differences.
In particular, if adequate observations and intensity data are
present for a peptide, then variance estimates can be attained
for the observed intensity values, and a standard t test or
ANOVA-based analysis can be performed; otherwise, the p-
value for ANOVA is 1. For missing data, the central question of
importance is whether the missing peptides are associated with
a particular experimental group; thus, if a peptide is observed
in all samples, the p-value for the G-test would be 1, and the
null hypothesis that the data are missing at random is not
rejected. The larger the p-value, the more likely the data are
simply missing in a random manner with respect to the
experimental groups. The combination of these two methods,
called IMD-ANOVA, therefore quantiﬁes signiﬁcance using
both peptide occurrence and peptide intensity and is per-
formed without imputation. A peptide may be signiﬁcant by
only one or both tests. For example, suppose a peptide is
observed in samples that represent three experimental treat-
ment groups and that the peptide is measured with high
frequency in the ﬁrst two groups but is missing (i.e., censored)
from the third group. This peptide would have a signiﬁcant
qualitative difference by the G-test. If there is a quantitative
difference between the measured intensity values in the ﬁrst
two groups, then it would also be signiﬁcant by ANOVA and
therefore would have a signiﬁcant result for both ANOVA and
G-test. If there was no quantitative difference between the
measured values in the ﬁrst two groups, then it would be
signiﬁcant by the G-test only.
Because we have shown that occurrence ﬁltering of the data
using a GA-ﬁlter eliminates peptides with inadequate data for
statistical analysis, we use the ﬁltered BALF and Plasma data
sets (Figure 1) to compare analysis approaches. Speciﬁcally,
we analyzed the peptide intensities to determine differences
identiﬁed as signiﬁcant for differential abundance by our
IMD-ANOVA approach and compared them with results from
ANOVA with the missing data imputed by LOD or KNN-1. KNN
with more neighbors (2, 3, and 4) was also evaluated (data not
shown) but correlated highly with KNN-1, and thus only results
using KNN-1 are presented.
The BALF and Plasma data sets consisted of 1733 and 5117
peptides, respectively, after the GA-ﬁlter (Figure 1). Using
IMD-ANOVA and a standard Benjamini-Hochberg
25 FDR
correction for multiple comparisons, the BALF and Plasma data
sets return 541 and 127 peptides, respectively, that are signiﬁ-
cant by either ANOVA or G-test (Figure 4) at a q-value of 0.05.
As seen in Figure 4, the same peptides are generally not
captured by both statistical tests. The signiﬁcant peptides
identiﬁed using the IMD-ANOVA approach were compared
to those identiﬁed by ANOVA after LOD or KNN-1 imputation
(Figure 5). A large number of peptides identiﬁed as signiﬁcant
by the G-test were not identiﬁed by ANOVA when the missing
data were imputed.
Figure 5 shows that there are many peptides identiﬁed as
signiﬁcant using only speciﬁc approaches, especially after
Figure 3. Overall graphical representation of the VN1203 data set.
The top graphic shows that the 255 identiﬁed viral peptides are
nearly all absent from the sham group (black) but have varying
abundance values in the virus group. On the bottom is a bar
graph that shows the number of peptides retained by the model-
based ﬁlter versus the GA-ﬁlter of the 20 viral proteins identiﬁed
by proteomics. Only 9 of these 20 proteins with known qualitative
differences are retained by the model-based ﬁlter, and those are
only represented by a small fraction of the total identiﬁed
peptides.
Figure 4. Overlap and uniqueness between the peptides identiﬁed
as signiﬁcant at an FDR corrected p-value of 0.05 by ANOVA and
G-test. The G-test for missing data identiﬁes signiﬁcant numbers
of peptides as having a treatment-related difference in occurrence.
Figure 5. Overlap and uniqueness between the peptides identiﬁed
as signiﬁcant at a FDR corrected p-value of 0.05 by IMD-ANOVA,
ANOVA LOD, and ANOVA KNN-1.
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cant prior to imputation. For example, the large number of
peptides unique to the ANOVA (KNN-1) illustrates a common
problem for KNN imputation: when peptide observations are
few, the chance of false positive signiﬁcance is increased
because one is imputing using intensities of a peptide which
does exhibit signiﬁcant differential abundance, even though
there are not adequate data in the raw form to make such an
inference. To demonstrate issues with imputation, we selected
several peptides for individual evaluation. The ﬁrst example
(ESTLHLVLR) shown in Figure 6 is a peptide signiﬁcant by
ANOVA which becomes nonsigniﬁcant after imputation, and
the second example (DLLFRDDTK) displays the reverse trend
(Figure 7), which is much more common.
For the peptide shown in Figure 6, the G-test returns a
p-value of 0.405; that is, there was no group for which the data
were missing at a greater frequency than expected by random
chance. In fact, the peptides are observed in g62.5% of the
samples within each group. This peptide also had sufﬁcient
data for ANOVA analysis, and the box plot in Figure 6A shows
a clear separation of the PA group from the FTN and control
groups, resulting in a p-value of 0.016 from ANOVA. Imputing
the missing values for this peptide with an LOD constant
(Figure 6B) signiﬁcantly changed the variance structure of the
data, especially for the PA group which became skewed by the
low intensity “outliers” that were introduced by imputation.
This LOD imputation caused a nonsigniﬁcant result (p-value
∼0.45 from ANOVA). The KNN-1 imputation was also prob-
lematic (Figure 6C) because the nearest neighbor peptide had
some very low intensities, which affected the variance of this
peptide (ESTLHLVLR) in a manner similar to the LOD imputa-
tion, resulting in a p-value of ∼0.47 from ANOVA.
Figure 6. Comparison of the boxplots and abundance values for (A)/(D) the raw data, (B)/(E) LOD imputed data, and (C)/(F) KNN-1
imputed data for peptide ESTLHLVLR. Peptide ESTLHVLR is signiﬁcant when analyzed by ANOVA when ignoring missing data (A) but
becomes nonsigniﬁcant after LOD or KNN-1 imputation due to variance introduced by the imputation method, (B) and (C), respectively.
Figure 7. Comparison of the boxplots and abundance values for (A)/(D) the raw data, (B)/(E) LOD imputed data, and (C)/(F) KNN-1
imputed data for peptide DLLFRDDTK. Peptide DLLFRDDTK is not signiﬁcant when analyzed by ANOVA when ignoring missing data
(A) but becomes signiﬁcant after LOD or KNN-1 imputation due to variance introduced by imputation, (B) and (C), respectively.
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in Figure 7 had observed intensity values in at least 75% of
samples across groups. Again, given the large number of
observed values in all groups, this peptide was not signiﬁcant
by G-test (p-value of 0.326). Evaluation of the raw data (Figure
7A, D) showed that except for a few low intensities in the
control group the peptide intensities are similar across groups,
and ANOVA appropriately returned a p-value of 0.134. How-
ever, when the missing values were imputed by LOD, the mean
of the control group was signiﬁcantly reduced, becoming
statistically smaller than the FTN group mean (p-value of 0.045),
but this signiﬁcance was merely an artifact because the FTN
group happened to be the one group with no missing observa-
tions and thus no imputed values. A similar artifactual signiﬁ-
cance is returned from KNN-1 because the imputed intensities
were not similar to the observed intensities. This example
illustrates the danger of imputing missing values and creating
false positive signiﬁcant peptides when the data clearly dem-
onstrate otherwise.
These examples demonstrate that the LOD and KNN-1
imputed values may introduce variance structures that cause
false positive and false negative results using ANOVA with the
imputed values. To be precise, the largest issue with imputation
is that it can alter the means and SDs of a peptide’s intensity
values, either creating artiﬁcial signiﬁcance or masking true
signiﬁcance. Examination of the subset of peptides signiﬁcant
by IMD-ANOVA but not ANOVA with imputation showed that
these are largely peptides present in only one or two groups
and absent from the others, demonstrating that the IMD-
ANOVA procedure performed as expected, successfully iden-
tifying censored peptides.
Conclusions
IMD-ANOVA integrates a statistical test across means
(ANOVA) with a statistical test of missing data (G-test) to yield
more accurate and sensitive results over common approaches
when analyzing measured peptide intensity values across
deﬁned treatment groups. The G-test is especially useful since
the results are not affected by other data processing procedures,
such as normalization. The G-test is based only on the number
of peptide observations and does not consider peptide intensi-
ties. The IMD-ANOVA approach was compared to ANOVA
(LOD) and ANOVA (KNN-1) to demonstrate that the variance
structure of the data can be adversely affected by the imputed
peptide intensities and that imputation ultimately creates
biases that change the signiﬁcance of a large number of
peptides. It is not surprising that imputation methods have
been difﬁcult to validate in proteomics, and very little has been
published in this area, particularly since truth is rarely known.
Even when data are missing from microarrays at random, the
results can be affected by imputation.
9,10,27 As noted by
Troyanskaya et al., regarding microarray analyses, “estimated
data should be ﬂagged where possible, and its signiﬁcance on
the discovery of biological results should be assessed to avoid
drawing unwarranted conclusions”.
8 Since the amount of
missing data in proteomics is much larger than its transcrip-
tomic counterpart (and not at random in many cases), the
proteomics community should be very cautious of methods
to impute missing data.
The primary beneﬁt of IMD-ANOVA is that it offers an
approach to analyze a proteomics data set in the presence of
missing data without further biasing the statistical conclusions.
As observed in Figure 3, the GA-ﬁltering approach retained
proteins with qualitative differences that are not evaluated in
model-based methods. Future work should determine the best
approach to the identiﬁcation of statistically signiﬁcant proteins
based on various levels of peptide evidence, such as G-test.
Lastly, ANOVA is available through any statistical package, and
the G-test is very easy to implement based on eq 2 using simple
counts of observed and absent intensity values for a peptide.
Code to generate the G-value and G-ﬁlter and to implement
the GA-ﬁlter is provided in Figures S4-S6 (Supporting Infor-
mation). Although the method is demonstrated at the peptide
level, the same methods for statistical analysis would be
applicable at the protein level.
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